Following Wednesday's market close, Steven Mento, president, CEO and co-founder of Conatus Pharmaceuticals Inc., carefully walked analysts and investors through the rationale, design and opportunities to learn from the phase IIb POLT-HCV-SVR trial of individuals with post-transplant fibrosis and cirrhosis – a group, he emphasized on the conference call, that's not been studied previously. Read More
Last August, after Merck & Co. Inc. disclosed positive but not especially compelling results with its cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, Credit Suisse analyst Vamil Divan concluded that the company made the right decision to quit, although drugs in the class "may still have a role in patients with certain genetic predispositions." Read More
Even though Humira's U.S. composition of matter patent expired more than a year ago and biosimilars are waiting to roll out, a basket lined with other patents will continue to protect Abbvie Inc.'s nest egg in the U.S. for a few more years. Read More
Healthy brains continue to generate new neurons into old age, though they show reduced neural plasticity and angiogenesis, researchers from Columbia University reported in the April 5, 2018, issue of Cell Stem Cell. Read More
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. has begun a U.S. phase II trial in glioblastoma with lead candidate GDC-0084, in-licensed from Roche Holding AG unit Genentech. Read More
Quralis Corp., of Cambridge, Mass., received undisclosed seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. The company is developing precision therapies to treat amyotrophic lateral sclerosis. Read More
Ohio Department of Insurance Director Jillian Froment issued a bulletin requiring heightened protections for Ohio consumers related to prescription drug prices. Read More
Elsalys Biotech SAS, of Lyon, France, is analyzing data from 147 patients with steroid-resistant graft-vs.-host disease treated with Leukotac (inolimomab) in an early access program. Read More
